Bionomics Investor Presentation Deck

BNC210 Phase 2 PREVAIL Social Anxiety Disorder Trial Acute Social Anxiety Disorder Study Highlights ✓ Cost-effective trial with an efficacy endpoint conducive to rapid data generation ✓ Ability to leverage VistaGen's development plan and trial design for Social Anxiety Disorder Received FDA clearance for IND filing and FDA Fast Track designation ✓ Phase 2 trial underway and will read out topline data by end of 2022 Bionomics LSAS = Liebowitz Social Anxiety Scale Phase 2 PREVAIL Study Design -50 225 mg BNC 210 60min SCREENING LSAS ≥ 70 RANDOMIZATION (DOUBLE-BLIND) -50 675 mg BNC 210 60min SINGLE ANXIETY CHALLENGE 台 frases -50 PLACEBO X 60min FDA Fast Track designation PREVAIL Study 13 LIEBOWITZ SOCIAL ANXIETY SCALE >95: Very severe social phobia 80-95: Severe social phobia 65-80: Marked social phobia 55-65: Moderate social phobia 15-20 CENTERS EFFICACY ENDPOINT SUBJECTIVE UNITS OF DISTRESS SCALE (SUDS): Measures the self-reported intensity of anxiety and/or distress in SAD patients Topline data YE'22

View entire presentation